PMID- 30138085
OWN - NLM
STAT- MEDLINE
DCOM- 20190913
LR  - 20200328
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 36
IP  - 29
DP  - 2018 Oct 10
TI  - Improved Survival for Children and Young Adults With T-Lineage Acute 
      Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 
      Methotrexate Randomization.
PG  - 2926-2934
LID - 10.1200/JCO.2018.77.7250 [doi]
AB  - PURPOSE: Early intensification with methotrexate (MTX) is a key component of 
      acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX 
      intensification exist but had not been compared in T-cell ALL (T-ALL): the 
      Children's Oncology Group (COG) escalating dose intravenous MTX without 
      leucovorin rescue plus pegaspargase escalating dose, Capizzi-style, intravenous 
      MTX (C-MTX) regimen and the Berlin-Frankfurt-Muenster (BFM) high-dose intravenous 
      MTX (HDMTX) plus leucovorin rescue regimen. PATIENTS AND METHODS: COG AALL0434 
      included a 2 x 2 randomization that compared the COG-augmented BFM (ABFM) regimen 
      with either C-MTX or HDMTX during the 8-week interim maintenance phase. All 
      patients with T-ALL, except for those with low-risk features, received 
      prophylactic (12 Gy) or therapeutic (18 Gy for CNS3) cranial irradiation during 
      either the consolidation (C-MTX; second month of therapy) or delayed 
      intensification (HDMTX; seventh month of therapy) phase. RESULTS: AALL0434 
      accrued 1,895 patients from 2007 to 2014. The 5-year event-free survival and 
      overall survival rates for all eligible, evaluable patients with T-ALL were 83.8% 
      (95% CI, 81.2% to 86.4%) and 89.5% (95% CI, 87.4% to 91.7%), respectively. The 
      1,031 patients with T-ALL but without CNS3 disease or testicular leukemia were 
      randomly assigned to receive ABFM with C-MTX (n = 519) or HDMTX (n = 512). The 
      estimated 5-year disease-free survival ( P = .005) and overall survival ( P = 
      .04) rates were 91.5% (95% CI, 88.1% to 94.8%) and 93.7% (95% CI, 90.8% to 96.6%) 
      for C-MTX and 85.3% (95% CI, 81.0%-89.5%) and 89.4% (95% CI, 85.7%-93.2%) for 
      HDMTX. Patients assigned to C-MTX had 32 relapses, six with CNS involvement, 
      whereas those assigned to HDMTX had 59 relapses, 23 with CNS involvement. 
      CONCLUSION: AALL0434 established that ABFM with C-MTX was superior to ABFM plus 
      HDMTX for T-ALL in approximately 90% of patients who received CRT, with later 
      timing for those receiving HDMTX.
FAU - Winter, Stuart S
AU  - Winter SS
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Dunsmore, Kimberly P
AU  - Dunsmore KP
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Devidas, Meenakshi
AU  - Devidas M
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Wood, Brent L
AU  - Wood BL
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Esiashvili, Natia
AU  - Esiashvili N
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Chen, Zhiguo
AU  - Chen Z
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Eisenberg, Nancy
AU  - Eisenberg N
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Briegel, Nikki
AU  - Briegel N
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Hayashi, Robert J
AU  - Hayashi RJ
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Gastier-Foster, Julie M
AU  - Gastier-Foster JM
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Asselin, Barbara L
AU  - Asselin BL
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Gaynon, Paul S
AU  - Gaynon PS
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Borowitz, Michael J
AU  - Borowitz MJ
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Loh, Mignon L
AU  - Loh ML
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Rabin, Karen R
AU  - Rabin KR
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Raetz, Elizabeth A
AU  - Raetz EA
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Zweidler-Mckay, Patrick A
AU  - Zweidler-Mckay PA
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Winick, Naomi J
AU  - Winick NJ
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Carroll, William L
AU  - Carroll WL
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
FAU - Hunger, Stephen P
AU  - Hunger SP
AD  - Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, 
      Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi 
      Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, 
      Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, 
      Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, 
      Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, 
      Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St 
      Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. 
      Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew 
      J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. 
      Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, 
      Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at 
      NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los 
      Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San 
      Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; 
      Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University 
      of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, 
      MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of 
      Pennsylvania, Philadelphia, PA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00408005
GR  - U24 CA196173/CA/NCI NIH HHS/United States
GR  - U10 CA098413/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - U10 CA180899/CA/NCI NIH HHS/United States
GR  - U10 CA180886/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180823
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 7D96IR0PPM (pegaspargase)
RN  - EC 3.5.1.1 (Asparaginase)
RN  - Q573I9DVLP (Leucovorin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
EIN - J Clin Oncol. 2019 Mar 20;37(9):761. PMID: 30875487
MH  - Adolescent
MH  - Adult
MH  - Antimetabolites, Antineoplastic/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Asparaginase/administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Infant
MH  - Leucovorin/administration & dosage
MH  - Male
MH  - Methotrexate/*administration & dosage
MH  - Polyethylene Glycols/administration & dosage
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/mortality
MH  - Young Adult
PMC - PMC6366301
EDAT- 2018/08/24 06:00
MHDA- 2019/09/14 06:00
PMCR- 2018/08/23
CRDT- 2018/08/24 06:00
PHST- 2018/08/24 06:00 [pubmed]
PHST- 2019/09/14 06:00 [medline]
PHST- 2018/08/24 06:00 [entrez]
PHST- 2018/08/23 00:00 [pmc-release]
AID - 777250 [pii]
AID - 10.1200/JCO.2018.77.7250 [doi]
PST - ppublish
SO  - J Clin Oncol. 2018 Oct 10;36(29):2926-2934. doi: 10.1200/JCO.2018.77.7250. Epub 
      2018 Aug 23.